Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Chemotherapy After SCRT in Locally Advanced Rectal Cancer
NCT06832917Phase 3Not yet recruiting
- Sponsor
- Shenzhen Wanhe Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies
01
Overview
Phase 3, randomised, open-label trial of cadonilimab in rectal cancer, sponsored by Shenzhen Wanhe Pharmaceutical. Primary endpoint: 3-year Disease Free Survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06832917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832917.